A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells
International Immunopharmacology · 2024-11 · 141 · 112794
DOI: 10.1016/j.intimp.2024.112794 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024-11. Verfasst von Jun Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Ch…. Hauptthemen laut MEDLINE: Ferroptosis, Diabetic Nephropathies, Saponins, Triterpenes. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
In China, the Astragalus membranaceus root is used to treat chronic kidney disease. Astragaloside IV (AS-IV), the primary bioactive compound, exhibits anti-inflammatory and antioxidative properties; however, its renoprotective mechanism in diabetic kidney disease (DKD) remains unclear. The study aimed to investigate the protective effects of AS-IV on DKD revealing the underlying mechanisms. We established an early diabetic rat model by feeding a high-fat diet and administering low-dose streptozotocin. Twelve weeks post-treatment, renal function was evaluated using functional assays, histological analyses, immunohistochemistry, western blotting, and transmission electron microscopy. HK-2 cells exposed to high glucose conditions were used to examine the effect of AS-IV on oxidative stress, iron levels, reactive oxygen species (ROS), and lipid peroxidation. Network pharmacology, proteomics, molecular docking, and molecular dynamics simulation techniques were employed to elucidate the role of AS-IV in DKD. The results revealed that AS-IV effectively enhanced renal function and mitigated disease pathology, oxidative stress, and ferroptosis markers in DKD rats. In HK-2 cells, AS-IV lowered the levels of lipid peroxides, Fe2+, and glutathione, indicating the repair of ferroptosis-related mitochondrial damage. AS-IV reduced mitochondrial ROS while enhancing mitochondrial membrane potential and ATP production, indicating its role in combating mitochondrial dysfunction. Overall, in silico analyses revealed that AS-IV interacts with HMOX1, FTH1, and TFR1 proteins, supporting its efficacy in alleviating renal injury by targeting mitochondrial dysfunction and ferroptosis. AS-IV may play a renoprotective role by regulating mitochondrial dysfunction and inhibiting. HMOX1/FTH1/TFR1-induced ferroptosis. Accordingly, AS-IV could be developed for the clinical treatment of DKD-related renal injury.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Combination of Chinese and Western Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention…
- College of Traditional Chinese Medicine, Chongqing Medical University, Chongqing 400016, China; Chongqing Key Laboratory of Traditional Chinese Medicine for Prevention and Cure of Metabolic Diseases, Chongqing 400016, C…
- Beibei Hospital of Traditional Chinese Medicine, Chongqing, 400700,China. Electronic address: 2640008075@qq.com.
- College of Traditional Chinese Medicine, Chongqing Medical and Pharmaceutical College,Chongqing 401331, China. Electronic address: 15320450137@163.com.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, J., Yang, K., Zhou, L., Deng, J., Rong, G., Shi, L., Zhang, X., Ren, J., Zhang, Y., & Cao, W. (2024). A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells. International Immunopharmacology, 141, 112794. https://doi.org/10.1016/j.intimp.2024.112794
Vancouver
Liu J, Yang K, Zhou L, Deng J, Rong G, Shi L, et al. A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells. International Immunopharmacology. 2024;141:112794. doi:10.1016/j.intimp.2024.112794
BibTeX
@article{Liu2024,
author = {Liu, Jun and Yang, Kang and Zhou, Linlan and Deng, Jingwei and Rong, Guoyi and Shi, Lipeng and Zhang, Xin and Ren, Jing and Zhang, Yudi and Cao, Wenfu},
title = {A new strategy for Astragaloside IV in the treatment of diabetic kidney disease: Analyzing the regulation of ferroptosis and mitochondrial function of renal tubular epithelial cells},
journal = {International Immunopharmacology},
year = {2024},
volume = {141},
pages = {112794},
doi = {10.1016/j.intimp.2024.112794}
}
EUVIMED